Cargando…
The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272618/ https://www.ncbi.nlm.nih.gov/pubmed/34256141 http://dx.doi.org/10.1016/j.cmi.2021.07.005 |
_version_ | 1783721252975804416 |
---|---|
author | Goletti, Delia Petrone, Linda Manissero, Davide Bertoletti, Antonio Rao, Sonia Ndunda, Nduku Sette, Alessandro Nikolayevskyy, Vladyslav |
author_facet | Goletti, Delia Petrone, Linda Manissero, Davide Bertoletti, Antonio Rao, Sonia Ndunda, Nduku Sette, Alessandro Nikolayevskyy, Vladyslav |
author_sort | Goletti, Delia |
collection | PubMed |
description | BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed. OBJECTIVES: To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB). SOURCES: PubMed articles up to 16 April 2021. CONTENT: T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4(+) and CD8(+) T-cell counts are markers of more severe disease, longer duration of viral RNA positivity and increased mortality. In line with natural infection, SARS-CoV-2 vaccination stimulates robust T-cell responses, which probably play an important role in protection; data on long-term T-cell responses are currently limited. The utility of measuring T-cell responses is already well established in both aiding the diagnosis of TB infection using IGRAs, and evaluation of T-cell responses to TB vaccine candidates. A variety of assays have already been developed to measure SARS-CoV-2-specific T-cell responses, including IGRAs, intracellular cytokine staining and activation-induced markers. IGRAs based on SARS-CoV-2 antigens can distinguish between convalescent and uninfected healthy blood donors. IMPLICATIONS: Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest. |
format | Online Article Text |
id | pubmed-8272618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82726182021-07-20 The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses Goletti, Delia Petrone, Linda Manissero, Davide Bertoletti, Antonio Rao, Sonia Ndunda, Nduku Sette, Alessandro Nikolayevskyy, Vladyslav Clin Microbiol Infect Narrative Review BACKGROUND: Both humoral and cell-mediated responses are associated with immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although our understanding of the potential role of T-cell responses in the context of coronavirus disease 2019 (COVID-19) is rapidly increasing, more information is still needed. OBJECTIVES: To provide an overview of the role of T-cell immunity in COVID-19, in the context of natural infection and post-vaccination, and discuss the potential utility of measuring SARS-CoV-2-specific T-cell responses, drawing on experience of the use of interferon-γ release assays (IGRAs) in tuberculosis (TB). SOURCES: PubMed articles up to 16 April 2021. CONTENT: T-cell responses can be detected very early in the course of COVID-19, earlier than the detection of antibody responses, and are correlated with COVID-19 outcome. Lower CD4(+) and CD8(+) T-cell counts are markers of more severe disease, longer duration of viral RNA positivity and increased mortality. In line with natural infection, SARS-CoV-2 vaccination stimulates robust T-cell responses, which probably play an important role in protection; data on long-term T-cell responses are currently limited. The utility of measuring T-cell responses is already well established in both aiding the diagnosis of TB infection using IGRAs, and evaluation of T-cell responses to TB vaccine candidates. A variety of assays have already been developed to measure SARS-CoV-2-specific T-cell responses, including IGRAs, intracellular cytokine staining and activation-induced markers. IGRAs based on SARS-CoV-2 antigens can distinguish between convalescent and uninfected healthy blood donors. IMPLICATIONS: Simple assays for measuring the quantity and function of T-cell responses may have utility in the prognostication of COVID-19, and for monitoring immune responses to SARS-CoV-2 vaccination and population-based immunity to SARS-CoV-2 variants of interest. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021-12 2021-07-10 /pmc/articles/PMC8272618/ /pubmed/34256141 http://dx.doi.org/10.1016/j.cmi.2021.07.005 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Narrative Review Goletti, Delia Petrone, Linda Manissero, Davide Bertoletti, Antonio Rao, Sonia Ndunda, Nduku Sette, Alessandro Nikolayevskyy, Vladyslav The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses |
title | The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses |
title_full | The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses |
title_fullStr | The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses |
title_full_unstemmed | The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses |
title_short | The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses |
title_sort | potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific t-cell responses |
topic | Narrative Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272618/ https://www.ncbi.nlm.nih.gov/pubmed/34256141 http://dx.doi.org/10.1016/j.cmi.2021.07.005 |
work_keys_str_mv | AT golettidelia thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT petronelinda thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT manisserodavide thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT bertolettiantonio thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT raosonia thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT ndundanduku thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT settealessandro thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT nikolayevskyyvladyslav thepotentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT golettidelia potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT petronelinda potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT manisserodavide potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT bertolettiantonio potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT raosonia potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT ndundanduku potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT settealessandro potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses AT nikolayevskyyvladyslav potentialclinicalutilityofmeasuringsevereacuterespiratorysyndromecoronavirus2specifictcellresponses |